On a Mission to Build Better Drugs
Peptone is the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.
Why we invested?
Francis Ho, a partner at Walden Catalyst, says “computational drug discovery is resurgent, but the missing piece is how to understand disordered proteins. We believe Peptone could be the key to completing this puzzle. The Peptone team possesses the right combination of world class scientific expertise, deep collaboration with top pharma and biotech partners, and incredible energy and passion to move mountains,” he says. “I’m excited to leverage our investment and operating track record of driving breakthroughs in Compute and Data/AI technologies to help Peptone further accelerate their vision.”